Cenobamate
Xcopri, Ontozry (cenobamate) is a small molecule pharmaceutical. Cenobamate was first approved as Xcopri on 2020-03-10. It is used to treat partial epilepsies in the USA. It has been approved in Europe to treat epilepsy. It is known to target gamma-aminobutyric acid receptor subunit alpha-4 and gamma-aminobutyric acid receptor subunit alpha-6. Xcopri maintenance pack's patent is valid until 2027-10-30 (FDA).
| Trade Name | Ontozry |
|---|---|
| Common Name | Cenobamate |
| Indication | epilepsy, partial epilepsies |
| Drug Class | Tranquilizers/antiepileptics (propanediol and pentanediol groups) |
